<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        149-276-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2004
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZIAGEN 20MG\ML ORAL SOLUTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ABACAVIR
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Oral solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        240
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        242.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GLAXOSMITHKLINE (GSK)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GLAXOSMITHKLINE (GSK)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Glaxo Saudi Arabia Ltd.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AF06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>ZIAGEN is used to treat HIV (human immunodeficiency virus) infection in adults and in children.</strong></p><p>ZIAGEN contains the active ingredient abacavir sulfate. This belongs to a group of anti-retroviral medicines called <em>nucleoside analogue reverse transcriptase inhibitors (NRTIs)</em>, which are used to treat HIV infection.</p><p>ZIAGEN does not cure HIV infection; it reduces the amount of virus in your body, and keeps it at a low level. It also increases the CD4 cell count in your blood. CD4 cells are a type of white blood cells that are important in helping your body to fight infection.</p><p>Not everyone responds to treatment with ZIAGEN in the same way. Your doctor will monitor the effectiveness of your treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Don&rsquo;t take/use ZIAGEN</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>allergic</strong> (hypersensitive) to abacavir (or any other medicine containing abacavir &mdash; <strong>Trizivir</strong> or <strong>Kivexa</strong>), or any other ingredients of ZIAGEN (listed in <strong>Section 6</strong>)</p><p><strong>Carefully read all the information about hypersensitivity reactions in Section 4.</strong></p><p>If you think this applies to you,<strong> don&rsquo;t take ZIAGEN</strong> until you have checked with your doctor.</p><p><em>&nbsp;</em></p><p><strong>Take special care with ZIAGEN</strong></p><p>Before you take ZIAGEN your doctor needs to know:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had <strong>liver disease,</strong> including hepatitis B or C&nbsp;</p><p><strong>Talk to your doctor if any of these apply to you</strong>. You may need extra check-ups, including blood tests, while you&rsquo;re taking your medication. <strong>See Section 4 for more information</strong>.</p><p>&nbsp;</p><p><strong>Conditions you need to look out for </strong></p><p>ZIAGEN can cause serious side effects.&nbsp; You must look out for certain symptoms while you are taking ZIAGEN, to reduce the risk of any problems.&nbsp;</p><p>&nbsp;</p><p><strong>Hypersensitivity reactions</strong></p><p>ZIAGEN contains abacavir. Abacavir can cause a serious allergic reaction known as a hypersensitivity reaction, which can be life-threatening if treatment with abacavir containing products is not stopped.</p><p><strong>Carefully read all the information about hypersensitivity reactions in Section 4 of this leaflet.</strong></p><p>&nbsp;</p><p><strong>Heart Disease</strong></p><p>Some studies have shown a small increase in the risk of having a heart attack in people taking abacavir, one of the active substances in ZIAGEN. Other studies have not shown any increased risk of heart attack in patients using abacavir</p><p><strong>Tell your doctor </strong>if you have heart problems, if you smoke, or have other illnesses that may increase your risk of heart disease such as high blood pressure, or diabetes. Don&rsquo;t stop taking ZIAGEN unless your doctor advises you to do so.</p><p>&nbsp;</p><p><strong>Old infections flaring up</strong></p><p>See &lsquo;<em>Conditions you need to look out for</em><em>&rsquo; </em>in <strong>Section 4</strong><em>.</em></p><p>&nbsp;</p><p><strong>Lactic acidosis</strong></p><p>A condition that is caused by build-up of lactic acid in the body.&nbsp; It is more likely to develop in people who have liver disease, especially in women.</p><p>See &lsquo;<em>Conditions you need to look out for</em><em>&rsquo; </em>in <strong>Section 4</strong><em>.</em></p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and ZIAGEN</strong></p><p><strong>Tell your doctor or pharmacist if you&#39;re taking any other medicines</strong>, if you&rsquo;ve taken any recently, or if you start taking new ones. This includes medicines bought without a prescription.</p><p>&nbsp;</p><p><strong>Methadone and </strong><strong>ZIAGEN</strong></p><p>If you are taking methadone, your doctor may need to adjust your methadone dose, as abacavir (the active substance in ZIAGEN) increases the rate at which methadone leaves your body. This is unlikely to affect most methadone users.</p><p>&nbsp;</p><p><strong>Riociguat and ZIAGEN</strong></p><p>If you are taking riociguat (a medicine used to treat high blood pressure in the</p><p>blood vessels (the pulmonary arteries) that carry blood from the heart to the lungs) your doctor may need to reduce your riociguat dose, as abacavir (the active substance in ZIAGEN) may increase riociguat blood levels.&nbsp;</p><p>Pregnancy</p><p>&nbsp;</p><p>If you are<strong> pregnant</strong>, or <strong>think you could be, </strong>or if you are <strong>planning to become pregnant</strong>, <strong>don&rsquo;t take ZIAGEN</strong> without checking with your doctor. <strong>&nbsp;Your doctor </strong>will weigh up the benefit to you against the risk to your baby of taking ZIAGEN while you&#39;re pregnant.</p><p>&nbsp;</p><p>In babies and infants exposed to NRTIs during pregnancy or labour small temporary increases in blood levels of a substance called lactate have been observed. Additionally, there have been very rare reports of diseases that affect the nervous system such as a delayed development and seizures. Overall, in children whose mothers took NRTIs during pregnancy, the benefit from the reduced chance of being infected with HIV is likely to be greater than the risk of suffering from side effects.</p><p>&nbsp;</p><p><strong>Breast-feeding</strong></p><p><strong>Where possible, women who are HIV-positive should not breast-feed</strong>.&nbsp; This is because HIV infection can be passed on to the baby in breast milk.&nbsp; If formula feeding is not possible, you should get advice from your doctor.</p><p>A small amount of the ingredients in ZIAGEN can also pass into your breastmilk.</p><p>&egrave;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Talk to your doctor immediately </strong>if you&rsquo;re breast-feeding, or thinking about breast-feeding.</p><p>&nbsp;</p><p><strong>While you&rsquo;re taking </strong><strong>ZIAGEN</strong></p><p><strong>You will need regular blood tests</strong></p><p>For as long as you&rsquo;re taking ZIAGEN, your doctor will arrange regular blood tests to check for side effects. There&rsquo;s more information about these side effects in <strong>Section 4 </strong>of this leaflet.</p><p><strong>Stay in regular contact with your doctor</strong></p><p>ZIAGEN helps to control your condition. You need to keep taking it every day to stop your illness getting worse. You may still develop other infections and illnesses linked to HIV infection.</p><p>&egrave;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Keep in touch with your doctor, and don&rsquo;t stop taking ZIAGEN</strong> without your doctor&rsquo;s advice.</p><p><strong>&nbsp;</strong></p><p><strong>Protect other people</strong></p><p>HIV infection is spread by sexual contact with someone who has the infection, or by transfer of infected blood (for example, by sharing injection needles). You can still pass on HIV when taking this medicine, although the risk is lowered by effective antiretroviral therapy. Discuss with your doctor the precautions needed to avoid infecting other people</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Always take ZIAGEN exactly as your doctor has told you to.</strong> Check with your doctor or pharmacist if you&#39;re not sure.</p><p>&nbsp;</p><p><strong>How much to take</strong></p><p>The usual dose of ZIAGEN in adults and in children weighing at least 25 kg is 600 mg a day. This can be taken as 300 mg (15 ml) twice a day, or 600 mg (30 ml) once a day, as advised by your doctor.&nbsp;</p><p>The recommended dose of ZIAGEN in children older than three months and weighing less than 25 kg is 8 mg/kg twice daily or 16 mg/kg once daily up to a maximum</p><p>dose of 300 mg twice daily or 600 mg once daily.</p><p>&nbsp;</p><p><strong>How to take/use</strong></p><p>Always take ZIAGEN exactly as your doctor has told you, and take great care not to miss any doses if at all possible. You should check with your doctor or pharmacist if you are not sure.</p><p>If your doctor wants to reduce your dose of ZIAGEN, for example if you have liver problems, then you may be prescribed abacavir as the oral solution.</p><p>Use the oral dosing syringe supplied with the oral solution to measure your dose accurately.</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp; Remove the plastic wrap from the syringe/adapter.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp; Remove the bottle cap.</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;Remove the adapter from the syringe.</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp; Push the adapter into the neck of the bottle, while holding the bottle firmly.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp; Insert the syringe firmly into the adapter.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp; Turn bottle upside down.</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp; Pull out syringe plunger until the correct amount is withdrawn.</p><p>8.&nbsp;&nbsp;&nbsp;&nbsp; Turn the bottle the correct way up and remove the syringe from the adapter.</p><p>9.&nbsp;&nbsp;&nbsp;&nbsp; Replace and tighten the bottle cap.</p><p>10.&nbsp; Administer the dose into the mouth by placing the tip of the syringe against the inside of the cheek.&nbsp; Slowly depress the plunger, allowing time to swallow. Forceful squirting to the back of the throat may cause choking.</p><p>&nbsp;</p><p>After use the syringe must not be left in the bottle and should be washed thoroughly in clean water.</p><p>If you forget to take/use ZIAGEN</p><p>&nbsp;</p><p><strong>Don&#39;t take a double dose </strong>to make up for a missed dose. Just take it as soon as you remember.</p><p>If you are not sure what to do, ask your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>If you take/use too much ZIAGEN</strong></p><p>If you take too much oral solution of ZIAGEN, <strong>contact your doctor or pharmacist, or your nearest hospital emergency department for advice.</strong> If possible, show them the ZIAGEN pack.</p><p>&nbsp;</p><p><strong>Don&rsquo;t stop ZIAGEN without advice</strong></p><p>If you have stopped taking ZIAGEN for any reason, particularly because you think you are having side effects or for other illness, it is important that you contact your doctor before restarting.&nbsp; In some cases, your doctor will ask you to restart ZIAGEN in a place where you will be able to get ready access to medical care if needed.</p><p>If you have hepatitis B infection, don&rsquo;t stop ZIAGEN without your doctor&rsquo;s advice, as your hepatitis may come back.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, ZIAGEN can cause side effects, although not everybody gets them.</p><p>When you&rsquo;re being treated for HIV, it can be hard to tell whether a symptom is a side effect of ZIAGEN or other medicines you are taking, or an effect of the HIV disease itself. <strong>So, it is very important to talk to your doctor about any changes in your health</strong>.</p><p><strong>ZIAGEN can cause a serious allergic reaction known as a hypersensitivity reaction,</strong> see &lsquo;Hypersensitivity reactions&rsquo; in <em>&lsquo;Conditions you need to </em></p><p><em>look out for&rsquo;</em> in <strong>Section 4</strong>.</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong></p><p><strong>It is very important that you read and understand the&nbsp; Information about this serious reaction</strong>.</p><p>&nbsp;</p><p><strong>As well as the side effects listed below for </strong><strong>ZIAGEN,</strong> other conditions can develop during combination therapy for&nbsp;HIV.</p><p>It is important to read the information in <em>&lsquo;Conditions you need to look out for&rsquo;</em> in <strong>Section 4.</strong></p><p>&nbsp;</p><p><strong>Conditions you need to look out for</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><p><strong>Hypersensitivity reactions</strong></p><p><strong>ZIAGEN </strong>contains <strong>abacavir</strong> (which is also an active ingredient in <strong>Kivexa, Trizivir</strong> and <strong>Triumeq</strong>).</p><p>Abacavir can cause a serious allergic reaction known as a hypersensitivity reaction, which can be life-threatening if treatment with abacavir containing products is not stopped.</p><p><strong>Who gets these reactions?</strong></p><p>Anyone taking ZIAGEN could develop a hypersensitivity reaction, which could be life threatening if they continue to take ZIAGEN.</p><p>You are more likely to develop such a reaction if you have a gene called<strong> HLA-B*5701</strong> (but you can get a reaction even if you don&rsquo;t have this gene). If possible, you will have been tested for this gene before ZIAGEN was prescribed for you. <strong>If you know you have this gene, tell your doctor before you take </strong><strong>ZIAGEN.</strong></p><p><strong>What are the symptoms?</strong></p><p>The most common symptoms are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Fever</strong> (high temperature) and <strong>skin rash</strong>.</p><p>Other common symptoms are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea (feeling sick), vomiting (being sick), diarrhoea, abdominal (stomach) pain, severe tiredness, shortness of breath, cough, headache, muscle pain and discomfort.</p><p>Other less common symptoms can include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pains in the joints , swelling of the neck, serious breathing problems, sore throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Occasionally, inflammation of the eye<em> (conjunctivitis)</em>, mouth ulcers, low blood pressure, tingling or numbness of the hands or feet.</p><p><strong>&nbsp;</strong></p><p><strong>When do these reactions happen?</strong></p><p>Hypersensitivity reactions can start at any time during treatment with ZIAGEN , but are more likely during the first 6 weeks of treatment.</p><p><strong>Contact your doctor immediately:</strong></p><p><strong>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you get a skin rash, OR</strong></p><p><strong>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you get symptoms from at least 2 of the following groups:</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Fever</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Shortness of breath, sore throat or cough</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Nausea or vomiting, diarrhoea or stomach pain</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - Severe tiredness or achiness, or generally feeling ill.</p><p>Your doctor may advise you to stop taking ZIAGEN</p><p><strong>Always carry your Alert Card while you are taking </strong><strong>ZIAGEN</strong><strong>.</strong></p><p><strong>If you have stopped taking </strong><strong>ZIAGEN </strong></p><p>If you have stopped taking ZIAGEN because of a hypersensitivity reaction, <strong>you must NEVER AGAIN take ZIAGEN, or any other medicine containing abacavir (Kivexa, Trizivir or Triumeq). </strong>If you do, within hours, your blood pressure could fall dangerously low which could result in death.</p><p>If you have stopped taking ZIAGEN &nbsp;for any reason &mdash; especially because you think you are having side effects, or because you have another illness:</p><p>&nbsp;</p><p><strong>Talk to your doctor before you start again. </strong>Your doctor will check whether your symptoms were related to a hypersensitivity reaction. If the doctor thinks they may have been,<strong> you will then be told never again to take ZIAGEN, or any other medicine containing abacavir. </strong>It is important that you follow this advice.</p><p>&nbsp;</p><p>Occasionally, reactions have developed in people who start taking abacavir again, and had only one symptom on the Alert Card before they stopped taking it.</p><p>Very rarely, reactions have developed in people who start taking abacavir again, but who had no symptoms before they stopped taking it.</p><p>If your doctor advises that you can start taking ZIAGEN again, you may be asked to take your first doses in a place where you will have ready access to medical care if you need it.</p><p>&nbsp;</p><p>If you are hypersensitive to ZIAGEN, return all your unused ZIAGEN tablets for safe disposal. Ask your doctor or pharmacist for advice.</p><p>&nbsp;</p><p>The ZIAGEN pack includes an <strong>Alert Card</strong>, to remind you and medical staff about hypersensitivity reactions. <strong>Detach this card and keep it with you at all times</strong>.</p></td></tr></tbody></table><p>Combination therapy such as ZIAGEN may cause other conditions to develop during HIV treatment.</p><p><strong>Old infections may flare up</strong></p><p>People with advanced HIV infection (AIDS) have weak immune systems, and are more likely to develop serious infections (opportunistic infections). When these people start treatment, they may find that old, hidden infections flare up, causing signs and symptoms of inflammation. These symptoms are probably caused by the body&rsquo;s immune system becoming stronger, so that the body starts to fight these infections.</p><p>If you get any symptoms of infection while you&rsquo;re taking ZIAGEN:</p><p><strong>Tell your doctor immediately</strong>. Don&rsquo;t take other medicines for the infection without your doctor&rsquo;s advice.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Lactic acidosis is a rare but serious side effect</strong></p><p>Some people taking ZIAGEN, or other medicines like it (NRTIs), develop a condition called lactic acidosis, together with an enlarged liver.</p><p>Lactic acidosis is caused by a build-up of lactic acid in the body. It is rare; if it happens, it usually develops after a few months of treatment. It can be life-threatening, causing failure of internal organs.</p><p>Lactic acidosis is more likely to develop in people who have liver disease, especially in women.</p><p><strong>Signs of lactic acidosis include:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>deep, rapid, difficult breathing</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>drowsiness</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>numbness </strong>or <strong>weakness</strong> in the limbs</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>feeling sick</strong> (nausea), <strong>being sick</strong> (vomiting)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>stomach pain</strong>.</p><p>During your treatment, your doctor will monitor you for signs of lactic acidosis. If you have any of the symptoms listed above or any other symptoms that worry you:</p><p>&egrave; <strong>See your doctor as soon as possible</strong>.</p><p>&nbsp;</p><p><strong>Common side effects</strong></p><p>These may affect <strong>up to 1 in 10 people:</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (<em>nausea</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypersensitivity reaction (<em>see &lsquo;hypersensitivity reactions&rsquo; section above</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being sick (<em>vomiting</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness, lack of energy</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high temperature(<em>fever</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash</p><p>&nbsp;</p><p><strong>Rare side effects </strong></p><p>These may affect <strong>up to 1 in 1000</strong> <strong>people</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lactic acidosis (see section<em>,</em> <em>&lsquo;Conditions you need to look out for&rsquo;</em>)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the pancreas (<em>pancreatitis</em>)</p><p>&nbsp;</p><p><strong>Very rare side effects</strong></p><p>These may affect <strong>up to 1 in 10,000 people</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash, which may form blisters and&nbsp; looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge)<em> (erythema multiforme)</em></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals<em> (Stevens&ndash;Johnson syndrome)</em>, and a more severe form causing skin peeling in more than 30% of the body surface <em>(toxic epidermal necrolysis)</em>.</p><p>If you notice any of these symptoms contact a doctor urgently.</p><p>&nbsp;</p><p><strong>Other effects may show up in blood tests</strong></p><p>Combination therapy for HIV can also cause:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>increased levels of lactic acid</strong> in the blood, which on rare occasions can lead to lactic acidosis</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>increased levels of sugar and fats</strong> (triglycerides and cholesterol) in the blood</p><p><strong>&nbsp;</strong></p><p><strong>If you get side effects</strong></p><p>&egrave;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Tell your doctor or pharmacist</strong> if any of the side effects become<strong> severe or&nbsp;&nbsp;&nbsp;&nbsp; troublesome</strong>, or if you notice any side effects not listed in this leaflet.</p><p>&nbsp;</p><p><strong>To report any side effect(s):&nbsp;</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><ul><li>Fax: +966-11-205-7662</li><li>Hotline: 19999</li><li>E-mail : npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa</li></ul><p><strong>-GlaxoSmithKline - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: gcc.medinfo@gsk.com &nbsp;&nbsp;&nbsp;</li><li>Website: https://gskpro.com/en-sa/ <u>&nbsp;</u></li><li>P.O Box 55850, Jeddah 21544, Saudi Arabia.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not take ZIAGEN after the expiry date shown on the pack or the bottle</p><p>Store ZIAGEN below 25 &deg;C.</p><p>Discard any remaining oral solution two months after first opening.</p><p>Don&rsquo;t dispose of any unwanted ZIAGEN tablets or ZIAGEN oral solution in your wastewater or household rubbish.</p><p>Ask your pharmacist how to dispose of medicines no longer required.&nbsp; This will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is abacavir sulfate.</p><p>The oral solution contains 20 mg of the active ingredient abacavir sulfate in each ml of the solution.</p><p>&nbsp;</p><p><strong>Oral Solution</strong></p><p>Sorbitol (34%)</p><p>Saccharin sodium</p><p>Sodium citrate</p><p>Citric acid anhydrous</p><p>Methyl parahydroxybenzoate (E218)</p><p>Propyl parahydroxybenzoate (E216)</p><p>Propylene glycol</p><p>Artificial strawberry and banana flavour</p><p>Purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                The oral solution is a clear to yellowish in colour with strawberry/banana flavouring. It is supplied in cartons containing a white polyethylene bottle, with a child resistant cap. The bottle contains 240 ml (20 mg abacavir sulfate/ml) of solution. A 10 ml oral dosing syringe and an adaptor for the bottle is included in the pack.



Not all presentations are available in every country.

ZIAGEN is trademark owned by or licensed to the ViiV Healthcare group of companies.
© 2021 GSK group of companies. All right reserved.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by: </strong></p><p>Bora Pharmaceutical Services Inc. Mississauga, Canada</p><p><strong>Packed by: </strong></p><p>Bora Pharmaceutical Services Inc. Mississauga, Canada</p><p><strong>Marketing Authorisation Holder&nbsp; </strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA.</p><p>Address: P.O. Box 22617 Jeddah 21416 &ndash; Kingdom of Saudi Arabia.</p><p><em>*member of the GlaxoSmithKline group of companies</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                GDS Version Number: 32
Version Date: 11 May 2020

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>زياچين</strong><strong> </strong><strong>يستعمل لعلاج عدوى ﭬـيروس </strong><strong>HIV</strong><strong> (ﭬـيروس نقص المناعة لدى البشر) لدى الكبار والأطفال.</strong></p><p dir="RTL"><strong>زياچين </strong>يحتوي على المكون الفعال سلفات الأباكاﭬـير. وهو ينتمي إلى مجموعة من الأدوية المضادة للـﭭـيروسات الإرتجاعية تدعى <em>مثبطات المنتسخة العكسية المضاهية للنوكليوزيد (</em><em>Nucleoside Analogue Reverse Transcriptase Inhibitors</em><em>) (</em><em>NRTIs</em><em>)، </em>والتي تستعمل لعلاج عدوى ﭬـيروس HIV.</p><p dir="RTL"><strong>زياچين </strong>لا يشفي عدوى ﭬـيروس HIV؛ إلا أنه يخفض كمية الـﭭـيروس في الجسم، ويبقيه عند مستوى منخفض. كما أنه يزيد أيضاً عد خلايا CD4 (Cluster of Differentiation) (عنقود التمايز) في الدم. خلايا CD4 هي أحد أنواع خلايا الدم البيضاء، ذات أهمية في مساعدة الجسم على محاربة العدوى.</p><p dir="RTL">لا يستجيب جميع الأفراد للعلاج <strong>بزياچين</strong> بنفس الطريقة. الطبيب سيراقب فعالية العلاج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا يجوز تناول/إستعمال زياچين</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت<strong> مصاباً بحساسية</strong> (مفرط الحساسية) للأباكاﭬـير (أو لأي دواء آخر يحتوي على الأباكاﭬـير ــــــــــــــــ <strong>تريزيـﭭـير</strong> أو <strong>كيـﭭـيكسا</strong>)، أو لأي من مكونات <strong>زياچين</strong><strong> </strong>الأخرى (المدرجة <strong>بالفقرة 6</strong>).</p><p dir="RTL"><strong>يرجى قراءة جميع المعلومات عن ردود الفعل الناتجة عن فرط الحساسية في الفقرة 4 بعناية.</strong></p><p dir="RTL">إذا ظننت أن ذلك ينطبق عليك، <strong>لا يجوز تناول زياچين</strong><strong> </strong>إلا بعد الرجوع إلى الطبيب.</p><p dir="RTL"><strong>يجب توخي الحذر الشديد عند إستعمال </strong><strong>زياچين في الحالات التالية</strong></p><p dir="RTL">قبل تناول <strong>زياچين، </strong>يجب أن يكون الطبيب على علم بالتالي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت سابقاً <strong>بمرض كبدي،</strong> بما في ذلك الإلتهاب الكبدي B أو C.</p><p dir="RTL"><strong>يجب التحدث مع الطبيب إذا كان أي مما سبق ذكره ينطبق عليك.</strong> قد تحتاج إلى إجراء فحوصات إضافية، بما في ذلك اختبارات الدم، أثناء تناول الدواء. <strong>انظر الفقرة 4 للمزيد من المعلومات.</strong></p><p dir="RTL"><strong>حالات يجب توخي الحذر منها</strong></p><p dir="RTL"><strong>زياچين</strong> قد يسبب آثاراً جانبية خطيرة. يجب توخي الحذر من ظهور أعراض معينة أثناء تناول <strong>زياچين</strong>، لتخفيض خطر حدوث أية مشاكل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ردود فعل ناتجة عن فرط الحساسية</strong></p><p dir="RTL"><strong>زياچين </strong>يحتوي على<strong> أباكاﭬـير, أباكاﭬـير</strong> قد ينشأ رد فعل ناتج عن فرط الحساسية &nbsp;(رد فعل أرجي خطير)، قد يهدد الحياة إذا واصلوا تناول الأباكاﭬـير.</p><p dir="RTL"><strong>يرجى قراءة جميع المعلومات عن ردود الفعل الناتجة عن فرط الحساسية في الفقرة 4 من هذه النشرة بعناية.</strong></p><p dir="RTL"><strong>أمراض قلبية</strong></p><p dir="RTL">أظهرت بعض الدراسات زيادة طفيفة في خطر الإصابة بنوبة قلبية لدى أفراد تناولوا الأباكاﭬـير، أحد المواد الفعالة في <strong>زياچين</strong>. لم تظهر الدراسات الأخرى أية زيادة في خطر الإصابة بنوبة قلبية لدى مرضى استعملوا الأباكاﭬـير.</p><p dir="RTL"><strong>يجب إبلاغ الطبيب</strong> إذا كنت تعاني من مشاكل قلبية، أو إذا كنت مدخناً، أو مصاباً بمرض آخر قد يسفر عن إرتفاع خطر الإصابة بمرض قلبي مثل إرتفاع ضغط الدم، أو السكري. لا يجوز وقف تناول <strong>زياچين</strong> إلا إذا نصحك الطبيب بذلك.</p><p dir="RTL"><strong>إحتدام عدوى قديمة</strong></p><p dir="RTL">أنظر<em> &quot;حالات يجب توخي الحذر منها&quot;</em> في <strong>الفقرة 4.</strong></p><p dir="RTL"><strong>حماض لاكتيكي</strong></p><p dir="RTL">وهي حالة ناتجة عن تجمع حمض اللاكتيك في الجسم. وتنشأ على الأرجح لدى أفراد مصابين بمرض كبدي، خاصةً لدى السيدات.</p><p dir="RTL">انظر<em> &quot;حالات يجب توخي الحذر منها&quot;</em> في <strong>الفقرة 4.</strong></p><p dir="RTL"><strong>الأدوية الأخرى و زياچين</strong></p><p dir="RTL"><strong>يجب إبلاغ الطبيب أو الصيدلي إذا كنت تتناول أية أدوية أخرى،</strong> أو إذا تناولت أية أدوية مؤخراً، أو إذا بدأت بتناول أدوية جديدة. وذلك يشمل الأدوية التي تشترى بدون وصفة طبية.</p><p dir="RTL"><strong>الميثادون و زياچين</strong></p><p dir="RTL">إذا كنت تتناول ميثادون، قد يحتاج الطبيب إلى تعديل جرعة الميثادون، نظراً لأن الأباكاﭬـير (أحد المواد الفعالة في <strong>زياچين) </strong>يزيد معدل خروج الميثادون من الجسم. من المستبعد أن يؤثر ذلك على معظم مستخدمي الميثادون.</p><p dir="RTL"><strong>ريوسيجوات وزياچين</strong></p><p>إذا كنت تتناول &quot;ريوسيجوات&quot; (دواء لعلاج ارتفاع ضغط الدم في الأوعية الدموية (التي تنقل الدم من القلب للرئتين)، فقد يحتاج طبيبك المعالج إلى تقليل جرعة ريوسيجوات، حيث أن أباكاﭬـير (المادة الفعّالة في عقار زياچين) قد تتسبب في ارتفاع تركيز عقار ريوسيجوت في الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">إذا كنت <strong>حامل</strong>، أو <strong>تظنين أنك قد تكونين حامل</strong>، أو إذا كنت <strong>تخططين للحمل، لا يجوز تناول زياچين</strong> دون الرجوع إلى الطبيب. <strong>الطبيب</strong> سيضع بعين الاعتبار المنفعة المتوقعة لك والمخاطر على طفلك الناتجة عن تناول <strong>زياچين</strong> أثناء الحمل.</p><p dir="RTL">لدى أطفال ورضع تعرضوا لمثبطات المنتسخة العكسية المضاهية للنوكليوزيد (NRTIs) أثناء الحمل أو الولادة، لوحظت زيادات طفيفة مؤقتة في مستويات مادة تدعى اللاكتات في الدم. بالإضافة إلى ذلك، وردت تقارير في حالات نادرة جداً عن أمراض تؤثر على الجهاز العصبي مثل تأخر النمو ونوبات صرع. إجمالاً، لدى أطفال تناولت أمهاتهم مثبطات المنتسخة العكسية المضاهية للنوكليوزيد (NRTIs) أثناء الحمل، المنفعة المتوقعة من تخفيض فرصة الإصابة بعدوى ﭬـيروس HIV تفوق غالباً خطر الإصابة بآثار جانبية.</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL"><strong>حيثما أمكن، لا تجوز الرضاعة الطبيعية لسيدات تم تأكيد إصابتهن بـﭭـيروس </strong><strong>HIV</strong><strong> بالإيجاب، </strong>نظراً لأن عدوى ﭬـيروس HIV قد تنتقل إلى الرضيع في حليب الثدي. إذا لم تكن التغذية البديلة عن الحليب ممكنة، يجب استشارة الطبيب.</p><p dir="RTL">قد تفرز أيضاً كمية ضئيلة من مكونات <strong>زياچين</strong> في حليب الثدي.</p><p dir="RTL"><strong>&not; </strong><strong>&nbsp;يجب التحدث مع الطبيب على الفور،</strong> إذا كنت ترضعين طفلك طبيعياً، أو تفكرين بإرضاع طفلك &nbsp;طبيعياً.</p><p dir="RTL"><strong>أثناء تناول زياچين </strong></p><p dir="RTL"><strong>ستحتاج لإجراء اختبارات للدم على نحو منتظم</strong></p><p dir="RTL">طالما تتناول <strong>زياچين</strong>، سيقوم الطبيب بترتيب اختبارات للدم على نحو منتظم للتأكد من عدم إصابتك بآثار جانبية. توجد معلومات إضافية عن هذه الآثار الجانبية في <strong>الفقرة 4</strong> من هذه النشرة.</p><p dir="RTL"><strong>ابقَ على اتصال بالطبيب على نحو منتظم</strong></p><p dir="RTL"><strong>زياچين</strong> يساعد على التحكم بحالتك. ويجب مواصلة تناوله كل يوم لمنع تدهور المرض لديك. إلا أنك لا تزال معرضاً للإصابة بعدوى وأمراض أخرى مرتبطة بعدوى ﭬـيروس HIV.</p><p dir="RTL"><strong>&not; </strong><strong>يجب البقاء على اتصال بالطبيب، ولا يجوز وقف تناول زياچين</strong> دون استشارة الطبيب.</p><p dir="RTL"><strong>وقاية الأشخاص الآخرين</strong></p><p dir="RTL">عدوى ﭬـيروس HIV تنتشر عن طريق الاتصال الجنسي مع شخص مصاب بالعدوى، أو عن طريق نقل دم يحمل العدوى (على سبيل المثال، عن طريق استعمال نفس الإبر للحقن). لا يزال بإمكانك نقل عدوى فيروس نقص المناعة المكتسب (الايدز) عند تناول هذا الدواء على الرغم من أن احتمالية انتقاله تقل مع استخدام العلاج الفعّال بالأدوية المضادة للـﭭـيروسات الإرتجاعية . لذا، يُرجى مناقشة الاحتياطات اللازمة مع طبيبك الخاص لتجنب نقل العدوى للأخرين</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>زياچين</strong> <strong>يجب تناوله دائماً وفقاً لتعليمات الطبيب.</strong> يجب الرجوع إلى الطبيب أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL"><strong>ما الجرعة التي يجب تناولها</strong></p><p dir="RTL">الجرعة المعتادة من <strong>زياچين</strong> لدى الكبار والأطفال الذين يبلغ وزنهم 25 كلجم على الأقل هي 600 ملجم في اليوم. ويجوز تناولها على هيئة 300 ملجم (15 مل) مرتين في اليوم، أو 600 (30 مل) ملجم مرة واحدة في اليوم، حسب تعليمات الطبيب.</p><p dir="RTL">الجرعة التي ينصح بها من <strong>زياچين</strong> للأطفال الذين يزيد عمرهم عن ثلاث أشهر ويقل وزنهم عن 25 كلجم هي 8 ملجم/كلجم مرتين في اليوم، أو 16 ملجم/كلجم مرة واحدة في اليوم حيث أن أقصى جرعة هي 300 ملجم مرتين في اليوم أو 600 ملجم مرة واحدة في اليوم.</p><p dir="RTL"><strong>كيفية تناول/إستعمال العقار </strong></p><p dir="RTL">زياچين يجب تناوله دائماً وفقاً لتعليمات الطبيب، ويجب الحرص جيداً على عدم تفويت أية جرعات قدر الإمكان. يجب الرجوع إلى الطبيب أو الصيدلي إذا لم تكن متأكداً.</p><p dir="RTL">إذا أراد الطبيب تخفيض جرعة <strong>زياچين</strong>، على سبيل المثال إذا كنت تعاني من مشاكل كبدية، حينها قد يوصف لك الأباكاﭬـير على هيئة محلول للإعطاء عن طريق الفم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إستخدم المحقنة الفموية لحساب الجرعات بدقة المتضمنة بالعلبة.</p><p dir="RTL">1-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بإزالة الغلاف البلاستيكي عن السرنجة أو المهيئ</p><p dir="RTL">2-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزل غطاء الزجاجة</p><p dir="RTL">3-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بإزالة المهيئ من السرنجة.</p><p dir="RTL">4-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إدفع المهيئ في عنق الزجاجة, بينما تمسك الزجاجة بحزم.</p><p dir="RTL">5-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدخل المحقنة بحزم في المهيئ.</p><p dir="RTL">6-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إقلب الزجاجة رأساً على عقب.</p><p dir="RTL">7-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسحب غطاس المحقنة حتى تصل إلى الكمية الصحيحة.</p><p dir="RTL">8-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعد الزجاجة إلى وضعها الصحيح و أخرج المحقنة من المهيئ.</p><p dir="RTL">9-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إستبدل وشد على غطاء الزجاجة.</p><p dir="RTL">10-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعطي الجرعة داخل الفم بوضع طرف المحقنة بمقابل داخل الخد. ببطئ إضغط الغطاس, لتسمح الوقت بالإبتلاع. تدفق الدواء بشدة في آخر الحلق قد يؤدي إلى الأختناق.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا نسيت تناول/استعمال زياچـين</strong></p><p dir="RTL"><strong>لا يجوز تناول جرعة مضاعفة</strong> للتعويض عن جرعة فائتة. يجب تناولها حالما تتذكر.</p><p dir="RTL">إذا لم تكن متأكداً، اسأل الطبيب أو الصيدلي.</p><p dir="RTL"><strong>إذا تناولت/استعملت أكثر مما يجب تناوله/استعماله من زياچـين</strong></p><p dir="RTL">إذا تناولت أكثر مما يجب تناوله من <strong>زياچـين</strong> أقراص أو محلول للإعطاء عن طريق الفم، <strong>يجب الاتصال بالطبيب أو الصيدلي، أو الذهاب إلى قسم الطوارىء بأقرب مستشفى للاستشارة.</strong> إن أمكن، اعرض عليهم عبوة <strong>زياچـين</strong>.</p><p dir="RTL"><strong>لا يجوز وقف تناول زياچـين دون استشارة</strong></p><p dir="RTL">في حالة وقف تناول <strong>زياچـين</strong> لأي سبب، خاصةً إذا كان السبب أنك تظن أنك تعاني من آثار جانبية أو بسبب مرض آخر، من المهم الاتصال بالطبيب قبل إعادة بدء العلاج. في بعض الحالات، سيطلب منك الطبيب إعادة بدء العلاج <strong>بزياچـين</strong> في مكان يتيح لك سهولة الوصول لرعاية طبية عند اللزوم.</p><p dir="RTL">إذا كنت مصاباً بعدوى ﭬـيروس الالتهاب الكبدي B، لا يجوز وقف تناول <strong>زياچـين</strong> دون استشارة الطبيب، نظراً لأنك قد تصاب بالتهاب كبدي مجدداً</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كشأن كافة الأدوية، <strong>زياچـين</strong> قد يسبب آثاراً جانبية، إلا أنها لا تصيب كل فرد.</p><p dir="RTL">عندما تعالج من ﭬـيروس HIV، قد يصعب تحديد ما إذا كان عرضٌ ما هو تأثير جانبي <strong>لزياچـين</strong> أو أدوية أخرى تتناولها، أو تأثير لمرض HIV ذاته. <strong>لذلك، من المهم جداً التحدث مع الطبيب بشأن أية تغيرات تطرأ على صحتك.</strong></p><p dir="RTL">نحو 5 أفراد من كل 100 فرد تناولوا الأباكاﭬـير أصيبوا برد فعل ناتج عن فرط الحساسية (رد فعل أرجي خطير)، انظر &quot;ردود فعل ناتجة عن فرط الحساسية<em>&quot;</em> تحت عنوان <em>&quot;حالات يجب توخي الحذر منها&quot;</em> في <strong>الفقرة 4. من المهم جداً قراءة وفهم المعلومات عن رد الفعل الخطير.</strong></p><p dir="RTL"><strong>علاوةً على الآثار الجانبية لزياچـين المدرجة أدناه،</strong> قد تنشأ حالات أخرى أثناء العلاج من ﭬـيروس HIV بتوليفة من الأدوية.</p><p dir="RTL">من المهم قراءة المعلومات تحت عنوان &nbsp;&quot;<em>حالات يجب توخي الحذر منها&quot;</em>في <strong>الفقرة 4.</strong></p><p dir="RTL"><strong>حالات يجب التنبه لها</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:800px"><tbody><tr><td><p dir="RTL"><strong>ردود فعل ناتجة عن فرط الحساسية</strong></p><p dir="RTL"><strong>زياچين </strong>يحتوي على<strong> أباكاﭬـير</strong> (وهو أيضاً المكون الفعال في <strong>تريزيـﭭـير</strong> و <strong>كيـﭭـيكسا و ترايامك</strong>).</p><p dir="RTL"><strong>أباكاﭬـير</strong> قد ينشأ رد فعل ناتج عن فرط الحساسية&nbsp; (رد فعل أرجي خطير)، قد يهدد الحياة إذا واصلوا تناول الأباكاﭬـير.</p><p dir="RTL"><strong>من يصاب بردود الفعل؟</strong></p><p dir="RTL">قد ينشأ رد فعل ناتج عن فرط الحساسية للأباكاﭬـير لدى أي فرد تناول زياچـين.</p><p dir="RTL">أنت أكثر عرضة للإصابة برد الفعل إذا كان لديك چين يدعى <strong>HLA-B*5701</strong> (إلا أنك قد تصاب برد فعل حتى إذا لم يكن لديك هذا الچين). إن أمكن، يجوز إجراء اختبار للتأكد من عدم وجود هذا الچين لديك قبل وصف <strong>زياچين</strong> لك. <strong>إذا كنت تعرف أنك تحمل هذا الچين، يجب إبلاغ الطبيب قبل تناول زياچين.</strong></p><p dir="RTL"><strong>ما هي الأعراض؟</strong></p><p dir="RTL">الأعراض الأكثر شيوعاً هي:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>حمى</strong> (ارتفاع الحرارة) و<strong>طفح جلدي.</strong></p><p dir="RTL">الأعراض الشائعة الأخرى هي:</p><p dir="RTL">غثيان (شعور بغثيان)، قيء (شعور بغثيان)، إسهال، ألم بالبطن (المعدة)، إرهاق شديد، ضيق النفس، سعال، صداع، ألم عضلي وانـزعاج.</p><p dir="RTL">الأعراض الأخرى الأقل شيوعاً قد تتضمن:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام بالمفاصل، تورم العنق، مشاكل خطيرة بالتنفس، التهاب الحلق.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحياناً، تورم العين <em>(التهاب الملتحمة)،</em> قرح بالفم، انخفاض ضغط الدم، وخز أو تنمل اليدين أو القدمين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>متى تحدث ردود الفعل؟</strong></p><p dir="RTL">ردود الفعل الناتجة عن فرط الحساسية قد تنشأ في أى وقت خلال العلاج <strong>بزياچين</strong>، إلا أنها تنشأ على الأرجح خلال الستة أسابيع الأولى من العلاج.</p><p dir="RTL"><strong>يجب الاتصال بالطبيب على الفور:</strong></p><p dir="RTL"><strong>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بطفح جلدي، أو</strong></p><p dir="RTL"><strong>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أصبت بأعراض من مجموعتين على الأقل من المجموعات التالية:</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - حمى.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - ضيق النفس، التهاب الحلق أو سعال.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - غثيان أو قيء، إسهال أو ألم بالمعدة.</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - إرهاق شديد أو شعور بالألم، أو شعور عام بالمرض.</p><p dir="RTL">قد ينصحك الطبيب بوقف تناول <strong>زياچين</strong>.</p><p dir="RTL"><strong>يجب دائماً الاحتفاظ بالبطاقة التحذيرية معك أثناء تناول زياچين.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة وقف تناول زياچين</strong></p><p dir="RTL">في حالة وقف تناول زياچين بسبب رد فعل ناتج عن فرط الحساسية، <strong>لا يجوز أبداً تناول زيا</strong><strong>چين مرة أخرى، أو أي دواء آخر يحتوي على الأباكاﭬـير (</strong><strong>تريزيـﭭـير أو كيـﭭـيكسا أو تلرايامك).</strong> في حالة تناول العقار، قد ينخفض ضغط الدم على نحو خطير، مما قد يسفر عن الوفاة.</p><p dir="RTL">إذا توقفت عن تناول زاياجن لأي سبب &ndash; خصوصاً بسبب إذا إعتقدت انك مصاب بأعراض جانبية, او بإي مرض اخر:</p><p dir="RTL">أخبر طبيبك قبل أن تبدأ مرة أخرى, طبيبك سوف يتحقق اذا ما كنت الأعراض الجانبية ردود فعل ناتجة عن فرط الحساسية, إذا اعتقد الطبيب أنها ردود فعل ناتجة عن فرط الحساسية, سوف يخبرك بعدم تناول <strong>زياچـين</strong> أو أي دواء يحتوي على<strong> أباكاﭬـير,</strong> من المهم إتباع هذه النصيحة.</p><p dir="RTL">فأحيانًا تظهر هذه التفاعلات لدى المرضى الذين بدأوا في تناول أباكاڤير مجددًا وسبق أن أصيبوا بواحد من الأعراض التي احتوت عليها بطاقة التنبيه قبل التوقف عن تناوله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ويندر ظهور هذه التفاعلات لدى المرضى الذين بدأوا في تناول أباكاڤير مجددًا ولم يسبق أن أصيبوا بأي من الأعراض قبل التوقف عن تناوله.</p><p>&nbsp;</p><p dir="RTL">إذا نصحك الطبيب باستئناف تناول زياچين مرة أخرى، فقد يُطلب منك تناول الجرعات الأولى في مكان يسهل فيه الحصول على العناية الطبية إن لزم الأمر.</p><p dir="RTL">إذا كنت تعاني من فرط الحساسية لعقار زياچين, فأعد جميع الأقراص غير المستخدمة حتى التخلص&nbsp; منها بشكل آمن. استشر الطبيب أو الصيدلاني.&nbsp;</p><p>تحتوي عبوة زياچين على <strong>بطاقة تنبيه</strong> لتذكيرك بالأمور الطبية المتعلقة بتفاعلات فرط الحساسية. <strong>أخرج هذه البطاقة واحتفظ بها معك طوال الوقت</strong><strong>. </strong></p></td></tr></tbody></table><p dir="RTL">العلاج بتوليفة من الأدوية مثل <strong>زياچين</strong> قد يسفر عن نشوء حالات أخرى أثناء العلاج من ﭬـيروس HIV.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إحتدام عدوى قديمة</strong></p><p dir="RTL">الأفراد المصابون بعدوى متقدمة بـﭭـيروس HIV (AIDS) لديهم أجهزة مناعية ضعيفة، وهم أكثر عرضة للإصابة بعدوى خطيرة (عدوى انتهازية).<em> </em>عندما يبدأ هؤلاء الأفراد العلاج، قد يجدون عدوى قديمة، كامنة تحتدم، مما يسفر عن ظهور علامات وأعراض التهاب. هذه الأعراض على الأرجح ناتجة عن ازدياد قوة الجهاز المناعي بالجسم، بحيث يبدأ الجسم بمحاربة هذه العدوى.</p><p dir="RTL">في حالة الإصابة بأية أعراض للعدوى أثناء تناول <strong>زياچين</strong>:</p><p dir="RTL"><strong>يجب إبلاغ الطبيب على الفور.</strong> لا يجوز تناول أدوية أخرى للعدوى دون استشارة الطبيب.</p><p dir="RTL"><strong>الحماض اللاكتيكي نادر إلا أنه تأثير جانبي خطير.</strong></p><p dir="RTL">بعض الأفراد الذين تناولوا <strong>زياچين</strong>، أو أدوية أخرى مشابهة له (مثبطات المنتسخة العكسية المضاهية للنوكليوزيد) (NRTIs)، أصيبوا بحالة تدعى حماض لاكتيكي، مصحوبة بتضخم الكبد.</p><p dir="RTL">الحماض اللاكتيكي ينتج عن تجمع حمض اللاكتيك في الجسم. ويحدث في حالات نادرة، وإن حدث، فهو ينشأ عادةً بعد أشهر قليلة من العلاج. وقد يهدد الحياة، مما يسفر عن فشل الأعضاء الداخلية.</p><p dir="RTL">الحماض اللاكتيكي ينشأ على الأرجح لدى أفراد مصابين بمرض كبدي، خاصةً لدى السيدات.</p><p dir="RTL"><strong>علامات الحماض اللاكتيكي تتضمن:</strong></p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تنفس عميق، سريع، مصحوب بصعوبة.</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>دوخة</strong>.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تنمل</strong> أو <strong>ضعف</strong> الأطراف.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>شعور بغثيان</strong> (غثيان)، <strong>شعور بغثيان</strong> (قيء).</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ألم بالمعدة.</strong></p><p dir="RTL">خلال العلاج، الطبيب سيراقب علامات الإصابة بحماض لاكتيكي. في حالة الإصابة بأي من الأعراض المدرجة أعلاه أو أي عرض آخر يقلقك:</p><p dir="RTL"><strong>&not;</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp; يجب رؤية الطبيب في أسرع وقت ممكن.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>آثار جانبية شائعة </strong></p><p dir="RTL">هذه التأثيرات قد تصيب<strong> ما يصل إلى فرد واحد من كل 10 </strong>أفراد<strong> </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بغثيان <em>(غثيان).</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل ناتج عن فرط الحساسية <em>(انظر فقرة &quot;ردود فعل ناتجة عن فرط الحساسية&quot; أعلاه&quot;).</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بغثيان <em>(قيء).</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إرهاق، نقص الطاقة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع الحرارة <em>(حمى).</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار جانبية نادرة</strong></p><p dir="RTL">هذه التأثيرات قد تصيب<strong> ما يصل إلى فرد واحد من كل 1000 </strong>فرد<strong> </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حماض لاكتيكي (انظر الفقرة ، <em>&quot;حالات يجب توخي الحذر منها&quot;</em>)<em>.</em></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>التهاب البنكرياس <em>(التهاب البنكرياس)</em></p><p dir="RTL"><strong>آثار جانبية نادرة جداً</strong></p><p dir="RTL">هذه التأثيرات قد تصيب<strong> ما يصل إلى فرد واحد من كل 10000 </strong>فرد<strong> </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، قد يتبثر، ويبدو مثل أهداف صغيرة (بقع مركزية داكنة اللون محاطة بمنطقة أكثر شحوباً، مع حلقة داكنة اللون حول الحافة) <em>(حمامى متعددة الأشكال).</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي واسع الانتشار مصحوب ببثرات وتقشر الجلد، خاصةً حول الفم، والأنف، والعينين، والأعضاء التناسلية <em>(متلازمة ستيـﭭـنـز چونسون)</em>، وشكل آخر أكثر شدة يسفر عن تقشر الجلد بنسبة تتجاوز 30% من سطح الجسم <em>(تقشر أنسجة البشرة الميتة التسممي).</em></p><p dir="RTL">إذا لاحظت أياً من هذه الأعراض، يجب الاتصال بالطبيب على وجه السرعة.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>آثار جانبية أخرى قد تظهر في اختبارات الدم</strong></p><p dir="RTL">علاج ﭬـيروس HIV بتوليفة من الأدوية قد يسبب أيضاً:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ارتفاع مستويات حمض اللاكتيك</strong> في الدم، مما قد يؤدي في حالات نادرة إلى الإصابة بحماض لاكتيكي.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ارتفاع مستويات السكر والدهون</strong> (الجليسريدات الثلاثية والكوليستيرول) في الدم.</p><p dir="RTL"><strong>في حالة الإصابة بآثار جانبية</strong></p><p dir="RTL"><strong>&not;</strong><strong>&nbsp;&nbsp;&nbsp;&nbsp; يجب إبلاغ الطبيب أو الصيدلي</strong> إذا أصبحت أي من الآثار الجانبية <strong>خطيرة أو تمثل مشكلة،</strong> أو إذا &nbsp; لاحظت أية آثار جانبية غير مدرجة في هذه النشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإبلاغ عن أية آثار جانبية</strong><strong>:</strong></p><p dir="RTL"><strong><em>المملكة العربية السعودية</em></strong></p><p dir="RTL"><strong>- المركز الوطني للتيقظ والسلامة الدوائية</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فاكس: 7662-205-11-966 +</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاتصال بالرقم الموحد: 19999</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p dir="RTL"><strong>- جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هاتف: 6536666 -12-966 +</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جوال: : -56-904-9882966+</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: saudi.safety@gsk.com</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://gskpro.com/en-sa/</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ص.ب 55850، جدة 21544، المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يحفظ بعيداً عن متناول ونظر الأطفال.</strong></p><p dir="RTL">لا يجوز استعمال زياچين بعد تاريخ انتهاء الصلاحية المبين على العبوة.</p><p dir="RTL">يحفظ زياچين بدرجة حرارة أقل من 25&deg; م.</p><p dir="RTL">تخلص من المحلول المتبقي بعد شهرين من أول فتح للزجاجة.إذا أخبرك الطبيب بوقف تناول تيـﭭـيكاي أقراص، فمن المهم إعادة أي كمية متبقية إلى الصيدلي.</p><p dir="RTL">لا يجوز التخلص من <strong>زياچين</strong> الغير مرغوب به في مياه الصرف الصحي أو المخلفات المنـزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ذلك يساعد على وقاية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي سلفات الأباكاﭬـير.</p><p>المحلول الفموي &nbsp;يحتوي على 20 ملجم / مل من المادة الفعالة سلفات الأباكاﭬـير في كل مل من المحلول.</p><p><strong>محلول للإعطاء عن طريق الفم</strong><em> </em></p><p><em>ساربيتول (34%)</em></p><p><em>ساكاريين صوديوم</em></p><p><em>صوديوم سيترات </em></p><p><em>صوديوم سيتريت</em></p><p><em>حمض السيترك لا مائي</em></p><p><em>ميثايل باراهيدروكسي بينزوايت </em><em>(E218)</em></p><p><em>بروبايل بارا هيدروكسي بينزووايت</em><em>(E216)</em></p><p><em>بروبيلين جليكول</em></p><p><em>نكهة فراولة وموز صناعية</em></p><p><em>ماء منقى</em></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>محلول للإعطاء للفم شفاف إلى الأصفر قليلاً بنكهة الفراولة/الموز. تقدم في علبة تحتوي على زجاجة بولي إثيلين أبيض. مع غطاء مقاوم للأطفال. الزجاجة تحتوي على 240 مل (20ملجم سلفات الأباكاﭬـير/مل) للمحلول. مع10 مل محقنة فموية لحساب الجرعات و مهايئ للزجاجة متضمنة بالعلبة.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">ليست جميع التراكيز و الأشكال متوفرة في جميع الدول.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>زياچين </strong>علامة تجارية مملوكة من أو مرخصة لمجموعة شركات ڤيڤ هيلثكير.</p><p dir="RTL">&copy; 2021 مجموعة شركات جلاكسو سميث كلاين.&nbsp; جميع الحقوق محفوظة</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة</strong><strong> </strong><strong>المنتجة</strong><strong>: </strong></p><p dir="RTL"><strong>&nbsp;</strong>بورا فارماسيوتيكالز سيرفيس إنك ، ميسيساكا ، كندا</p><p dir="RTL"><strong>&nbsp;</strong><strong>تعبئة:</strong></p><p dir="RTL">بورا فارماسيوتيكالز سيرفيس إنك ، ميسيساكا ، كندا</p><p dir="RTL"><strong>حامل</strong><strong> </strong><strong>ترخیص</strong><strong> </strong><strong>التسویق</strong><strong>:</strong></p><p dir="RTL"><strong>&nbsp;</strong>جلاكسو العربية السعودية المحدودة * ، جدة، المملكة العربية السعودية</p><p dir="RTL">*عضو مجموعة شركات جلاكسوسميث كلاين</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            رقم النص: GDS32
تاريخ النص: 11 مايو 2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ZIAGEN™ contains 20 mg/ml of abacavir.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ZIAGEN oral solution contains 20 mg/ml of abacavir as abacavir sulfate. ZIAGEN oral solution is a clear to slightly opalescent yellowish, aqueous solution which may turn into a brown colour over time with strawberry/banana flavouring.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oral solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>ZIAGEN</em> is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults and children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapy should be initiated by a physician experienced in the management of HIV infection.</p><p><em>ZIAGEN</em> can be taken with or without food.</p><p>For patients who are unable to swallow tablets, Ziagen is available as an oral solution. Alternatively, the tablets may be crushed and added to a small amount of semi-solid food or liquid, all of which should be consumed immediately <em>(see Pharmacokinetics)</em>.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Adults<em>,</em> adolescents<em> and children</em> weighing at least <em>25</em> kg</strong></p><p>The recommended dose of <em>ZIAGEN</em> oral solution is 300&nbsp;mg (15&nbsp;ml) twice daily<strong><em> </em></strong>or 600 mg (30 ml) once daily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Children from three months and weighing less than <em>25</em> kg</strong></p><p>The recommended dose is 8&nbsp;mg/kg twice daily or 16 mg/kg once daily up to a maximum dose of 300 mg twice daily or 600 mg once daily.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Children less than three months</strong></p><p>The data available on the use of <em>ZIAGEN</em> in this age group are very limited (<em>see Pharmacokinetics</em>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Renal impairment</strong></p><p>No dosage adjustment of <em>ZIAGEN</em> is necessary in patients with renal dysfunction (<em>see Pharmacokinetics</em>).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hepatic impairment</strong></p><p>Abacavir is metabolised primarily by the liver. The recommended dose of <em>ZIAGEN</em> in patients with mild hepatic impairment (Child-Pugh score 5 to 6) is 200&nbsp;mg (10&nbsp;ml) twice a day. To enable dose reduction <em>ZIAGEN</em> oral solution should be used for the treatment of these patients. Pharmacokinetic and safety data on the use of abacavir in patients with moderate and severe hepatic impairment are not available (see Pharmacokinetics). Therefore, the use of ZIAGEN is not recommended in patients with moderate or severe hepatic impairment, unless the benefit of use outweighs the risk</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ZIAGEN is contraindicated in patients with known hypersensitivity to abacavir or any ingredient of ZIAGEN tablets or oral solution.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="1" cellpadding="1" style="width:850px"><tbody><tr><td><p>Hypersensitivity (see Adverse Reactions)</p><p>Abacavir is associated with a risk for hypersensitivity reactions (HSR) characterized by fever and/or rash with other symptoms indicating multi-organ involvement. HSR can be life-threatening, and in rare cases fatal, when not managed appropriately. The risk for abacavir HSR to occur is significantly increased for patients who test positive for the HLA-B*5701 allele. However, abacavir HSRs have been reported at a lower frequency in patients who do not carry this allele.&nbsp;</p><p>The following should be adhered to:</p><p>Testing for HLA-B*5701 status should be considered before initiating abacavir treatment and also before re-starting abacavir treatment in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.</p><p>ZIAGEN is not recommended for use in patients with the HLA-B*5701 allele, or in patients who have had a suspected abacavir HSR while taking any other medicinal product containing abacavir (e.g. KIVEXA, TRIZIVIR, TRIUMEQ) regardless of HLA-B*5701 status.</p><p>Each patient should be reminded to read the Patient Leaflet included in the ZIAGEN pack. They should be reminded of the importance of removing the Alert Card included in the pack, and keeping it with them at all times.</p><p>In any patient treated with ZIAGEN, the clinical diagnosis of suspected hypersensitivity reaction must remain the basis of clinical decision making.</p><p>ZIAGEN must be stopped without delay, even in the absence of the HLA-B*5701 allele, if a HSR is suspected. Delay in stopping treatment with ZIAGEN after the onset of hypersensitivity may result in a life-threatening reaction.</p><p>Patients who have experienced a hypersensitivity reaction should be instructed to dispose of their remaining ZIAGEN tablets in order to avoid restarting abacavir.</p><p>Restarting abacavir containing products following a suspected abacavir HSR can result in a prompt return of symptoms within hours, and may include life-threatening hypotension and death.</p><p>Regardless of a patient&rsquo;s HLA-B*5701 status, if therapy with any abacavir containing product has been discontinued for any reason and restarting abacavir therapy is under consideration, the reason for discontinuation must be established.&nbsp; If HSR cannot be ruled out, ZIAGEN or any other medicinal product containing abacavir (e.g. KIVEXA, TRIZIVIR, TRIUMEQ) must not be restarted.</p><p>If a hypersensitivity reaction is ruled out, patients may restart ZIAGEN. Rarely, patients who have stopped abacavir for reasons other than symptoms of HSR have also experienced life-threatening reactions within hours of re- initiating abacavir therapy (see Section 4.8 Description of selected adverse reactions). Patients must be made aware that HSR can occur with reintroduction of ZIAGEN or any other medicinal product containing abacavir (e.g. KIVEXA, TRIZIVIR, TRIUMEQ) and that reintroduction of ZIAGEN or any other medicinal product containing abacavir (e.g. KIVEXA, TRIZIVIR, TRIUMEQ) should be undertaken only if medical care can be readily accessed.</p><p>Clinical Description of abacavir HSR</p><p>Abacavir HSR has been well characterised through clinical studies and during post marketing follow-up. Symptoms usually appeared within the first six weeks (median time to onset 11 days) of initiation of treatment with abacavir, although these reactions may occur at any time during therapy.</p><p>Almost all HSR to abacavir include fever and/or rash as part of the syndrome.</p><p>Other signs and symptoms that have been observed as part of abacavir HSR include respiratory and gastrointestinal symptoms, which may lead to misdiagnosis of HSR as respiratory disease (pneumonia, bronchitis, pharyngitis), or gastroenteritis (see Adverse Reactions, Description of Selected Adverse Reactions). The symptoms related to HSR worsen with continued therapy and can be life threatening. These symptoms usually resolve upon discontinuation of ZIAGEN.</p></td></tr></tbody></table><p>&sect;&nbsp; <strong>Lactic Acidosis/Severe Hepatomegaly with Steatosis</strong></p><p>Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of antiretroviral nucleoside analogues either alone or in combination, including abacavir.&nbsp; A majority of these cases have been in women.&nbsp;</p><p>Clinical features which may be indicative of the development of lactic acidosis include generalised weakness, anorexia, and sudden unexplained weight loss, gastrointestinal symptoms and respiratory symptoms (dyspnoea and tachypnoea).</p><p>&sect;&nbsp; Caution should be exercised when administering <em>ZIAGEN </em>particularly to those with known risk factors for liver disease. Treatment with <em>ZIAGEN</em> should be suspended in any patient who develops clinical or laboratory findings suggestive of lactic acidosis with or without hepatitis<strong><em> </em></strong>(which may include hepatomegaly and steatosis even in the absence of marked transaminase elevations).</p><p>&sect;&nbsp;&nbsp; Serum lipids and blood glucose</p><p>Serum lipid and blood glucose levels may increase during antiretroviral therapy. Disease control and life style changes may also be contributing factors. Consideration should be given to the measurement of serum lipids and blood glucose. Lipid disorders should be managed as clinically appropriate.</p><p>&nbsp;</p><p><strong>&sect;&nbsp; Immune Reconstitution Syndrome</strong></p><p>In HIV-infected patients with severe immune deficiency at the time of initiation of anti-retroviral therapy (ART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of ART.&nbsp; Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections and <em>Pneumocystis jiroveci </em>pneumonia (often referred to as PCP). Any inflammatory symptoms must be evaluated without delay and treatment initiated when necessary.<strong><em> </em></strong>Autoimmune disorders (such as Graves&rsquo; disease, polymyositis and Guillain-Barre syndrome) have also been reported to occur in the setting of immune reconstitution, however, the time to onset is more variable, and can occur many months after initiation of treatment and sometimes can be an atypical presentation.</p><p>&sect;&nbsp; <strong>Opportunistic infections</strong></p><p>Patients receiving <em>ZIAGEN</em> or any other antiretroviral therapy may still develop opportunistic infections and other complications of HIV infection. Therefore patients should remain under close clinical observation by physicians experienced in the treatment of these associated HIV diseases.</p><p>&sect;&nbsp; <strong>Transmission of infection</strong></p><p>While effective viral suppression with antiretroviral therapy has been proven to substantially reduce the risk of sexual transmission, a residual risk cannot be excluded. Precautions to prevent transmission should be taken in accordance in accordance with national guidelines.</p><p>&sect;&nbsp; <strong>Myocardial Infarction</strong></p><p>Several observational, epidemiological studies have reported an association with abacavir use and the risk of myocardial infarction. Meta-analyses of randomised controlled trials have observed no excess risk of myocardial infarction with abacavir use. To date, there is no established biological mechanism to explain a potential increase in risk. In totality the available data from observational studies and from controlled clinical trials show inconsistency and therefore the evidence for a causal relationship between abacavir treatment and the risk of myocardial infarction is inconclusive.</p><p>As a precaution the underlying risk of coronary heart disease should be considered when prescribing antiretroviral therapies, including abacavir, and action taken to minimize all modifiable risk factors (e.g. hypertension, hyperlipidaemia, diabetes mellitus and smoking).</p><p><strong><em>Oral solution:</em></strong></p><p><em>ZIAGEN</em> oral solution contains sorbitol which may cause abdominal pain and diarrhoea. Sorbitol is metabolised to fructose and is therefore unsuitable for patients who have hereditary fructose intolerance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The potential for drug interactions involving abacavir is low. <strong><em>In vitro studies have shown that abacavir has potential to inhibit cytochrome P450 1A1 (CYP1A1).</em></strong> Abacavir shows limited potential to inhibit metabolism mediated by the CYP3A4 enzyme. It has also been shown <em>in vitro</em> not to interact with drugs that are metabolised by CYP2C9 or CYP2D6 enzymes. Induction of hepatic metabolism has not been observed in clinical studies. Therefore, there is little potential for drug interactions with antiretroviral protease inhibitors and other drugs metabolised by major CYP<sub> </sub>enzymes. Clinical studies have shown that there are no clinically significant interactions between abacavir, zidovudine and lamivudine.</p><p>&nbsp;</p><p><strong><em>Effect of Abacavir on the Pharmacokinetics of Other Agents</em></strong></p><p>In vitro, abacavir demonstrates no or weak inhibition of the drug transporters organic anion transporter 1B1 (OATP1B1), OATP1B3, breast cancer resistance protein (BCRP) or P-glycoprotein (Pgp) and minimal inhibition of organic cation transporter 1 (OCT1), OCT2 and multidrug and toxin extrusion protein 2-K (MATE2-K). Abacavir is therefore not expected to affect the plasma concentrations of drugs that are substrates of these drug transporters.</p><p>Abacavir is an inhibitor of MATE1 in vitro, however abacavir has low potential to affect the plasma concentrations of MATE1 substrates at therapeutic drug exposures (up to 600 mg).&nbsp;</p><p><strong><em>Effect of Other Agents on the Pharmacokinetics of Abacavir </em></strong></p><p>In vitro, abacavir is not a substrate of OATP1B1, OATP1B3, OCT1, OCT2, OAT1, MATE1, MATE2-K, Multidrug resistance-associated protein 2 (MRP2) or MRP4,&nbsp; therefore drugs that modulate these transporters are not expected to affect abacavir plasma concentrations.</p><p>Although abacavir is a substrate of BCRP and Pgp in vitro, clinical studies demonstrate no clinically significant changes in abacavir pharmacokinetics when co-administered with lopinavir/ritonavir (Pgp and BCRP inhibitors).</p><p><strong><em>Interactions relevant to abacavir</em></strong></p><p><strong><em>Ethanol:</em> </strong>The metabolism of abacavir is altered by concomitant ethanol resulting in an increase in AUC of abacavir of about 41%. Given the safety profile of abacavir these findings are not considered clinically significant. Abacavir has no effect on the metabolism of ethanol.</p><p><strong><em>Methadone</em></strong><strong>:</strong> In a pharmacokinetic study, coadministration of 600 mg <em>ZIAGEN</em> twice daily with methadone showed a 35% reduction in abacavir C<sub>max</sub> and a 1 h delay in t<sub>max</sub>, but the AUC was unchanged. The changes in abacavir pharmacokinetics are not considered clinically relevant. In this study abacavir increased the mean methadone systemic clearance by 22 %. This change is not considered clinically relevant for the majority of patients, however, occasionally methadone re-titration may be required.</p><p><strong><em>Retinoids:</em></strong> Retinoid compounds such as isotretinoin, are eliminated via alcohol dehydrogenase. Interaction with abacavir is possible but has not been studied.</p><p><strong><em>Riociguat:</em></strong> In vitro, abacavir inhibits CYP1A1. Concomitant administration of a single dose of riociguat (0.5 mg) to HIV patients receiving the combination of abacavir/dolutegravir/lamivudine (600mg/50mg/300mg once daily) led to an approximately three-fold higher riociguat AUC(0-&infin;) when compared to historical riociguat AUC(0-&infin;) reported in healthy subjects. Riociguat dose may need to be reduced, consult the riociguat product labeling for dosing recommendations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>Pregnancy </em></strong></p><p>Abacavir has been evaluated in the Antiretroviral Pregnancy Registry in over 2000 women during pregnancy and postpartum. Available human data from the Antiretroviral Pregnancy Registry do not show an increased risk of major birth defects for abacavir compared to the background rate (see Clinical Studies). However, there are no adequate and well-controlled trials in pregnant women and the safe use of <em>ZIAGEN</em> in human pregnancy has not been established. Abacavir has been associated with findings in animal reproductive studies (<em>see Pre-clinical Safety Data</em>). Therefore, administration of <em>ZIAGEN</em> in pregnancy should be considered only if the benefit to the mother outweighs the possible risk to the foetus.</p><p>There have been reports of mild, transient elevations in serum lactate levels, which may be due to mitochondrial dysfunction, in neonates and infants exposed <em>in utero</em> or peri-partum to NRTIs. The clinical relevance of transient elevations in serum lactate is unknown. There have also been very rare reports of developmental delay, seizures and other neurological disease. However, a causal relationship between these events and NRTI exposure <em>in utero</em> or peri-partum has not been established. These findings do not affect current recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV</p><p><strong><em>Lactation</em></strong></p><p>Health experts recommend that where possible HIV infected women do not breast feed their infants in order to avoid transmission of HIV.&nbsp; In settings where formula feeding is not feasible, local official lactation and treatment guidelines should be followed when considering breast feeding during antiretroviral therapy.</p><p>In a study after repeat oral administration of 300 mg abacavir twice daily (given as TRIZIVIR), the breast milk: maternal plasma: ratio was 0.9. Most infants (8 out of 9) had non-detectable levels of abacavir (assay sensitivity 16ng/mL). Intracellular carbovir triphosphate (active metabolite of abacavir) levels in breastfed infants were not measured therefore the clinical relevance of the serum concentrations of the parent compound measured is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No currently available data suggest that <em>ZIAGEN</em> affects the ability to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For many of the other adverse events reported, it is unclear whether they are related to <em>ZIAGEN</em>, to the wide range of medicinal products used in the management of HIV disease or as a result of the disease process.</p><p>&nbsp;</p><p>Many of those listed below (nausea, vomiting, diarrhoea, fever, fatigue, rash) occur commonly as part of <em>ZIAGEN</em> hypersensitivity. Therefore, patients with any of these symptoms should be carefully evaluated for the presence of this hypersensitivity reaction. If <em>ZIAGEN</em> has been discontinued in patients due to experiencing any one of these symptoms and<strong> </strong>a decision is made to restart <em>ZIAGEN</em>, this should be done only under direct medical supervision (<em>see Warnings and Precautions - &ldquo;Special considerations following an interruption of ZIAGEN therapy&rdquo;</em>).</p><p>The majority of the adverse reactions listed below have not been treatment limiting. The following convention has been used for their classification: very common (more than 1/10), common (more than 1/100, less than 1/10), uncommon (more than 1/1,000, less than 1/100), rare (more than 1/10,000, less than 1/1,000) very rare (less than 1/10,000).</p><p>Clinical Trial Data</p><p>Metabolism and nutrition disorders&nbsp;</p><p>Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anorexia.</p><p>&nbsp;</p><p><strong>Nervous system disorders</strong></p><p>Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache.</p><p><strong>Gastrointestinal disorders</strong></p><p>Common:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea, vomiting, diarrhoea.</p><p><strong>General disorders and administration site disorders</strong></p><p>Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever, lethargy, fatigue.</p><p>In controlled clinical studies laboratory abnormalities related to <em>ZIAGEN</em> treatment were uncommon, with no differences in incidence observed between <em>ZIAGEN</em> treated patients and the control arms.</p><p><em>Paediatric population</em></p><p>The safety database to support abacavir once daily dosing in paediatric patients comes from the ARROW Trial (COL105677) in which 669 HIV-1 infected paediatric subjects received abacavir and lamivudine either once or twice daily (see Clinical Studies). No additional safety issues have been identified in paediatric subjects receiving either once or twice daily dosing compared to adults.</p><p>Post-marketing Data</p><p>Metabolism and nutrition disorders&nbsp;</p><p>Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hyperlactataemia.</p><p>Rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lactic acidosis (<em>see Warnings and Precautions)</em>.</p><p><strong>Gastrointestinal disorders</strong><em> </em></p><p>Rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pancreatitis has been reported, but a causal relationship to <em>ZIAGEN</em> treatment is uncertain.</p><p>Skin and subcutaneous tissue disorders</p><p>Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash (without systemic symptoms).</p><p>Very rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis.</p><p>Description of Selected Adverse Reactions</p><p>Hypersensitivity (see also Warnings and Precautions):</p><p><em>Abacavir hypersensitivity reaction (HSR) has been identified as a common adverse reaction with abacavir therapy. The signs and symptoms of this hypersensitivity reaction are listed below. These have been identified either from clinical studies or post marketing surveillance. Those reported in at least 10% of patients with a hypersensitivity reaction are in bold text.</em></p><p><em>Almost all patients developing hypersensitivity reactions will have fever and/or rash (usually maculopapular or urticarial) as part of the syndrome, however, reactions have occurred without rash or fever. Other key symptoms include gastrointestinal, respiratory or constitutional symptoms such as lethargy and malaise.</em></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><em>Skin: </em></p></td><td style="vertical-align:top"><p><em>&nbsp;Rash (usually maculopapular or urticarial)</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Gastrointestinal tract:</em></p></td><td style="vertical-align:top"><p><em>&nbsp;Nausea, vomiting, diarrhoea, abdominal pain, mouth ulceration</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory tract:</em></p></td><td style="vertical-align:top"><p><em>&nbsp;Dyspnoea, cough, sore throat, adult respiratory distress syndrome, respiratory failure</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Miscellaneous: </em></p></td><td style="vertical-align:top"><p><em>&nbsp;Fever, fatigue, malaise, oedema, lymphadenopathy, hypotension, conjunctivitis, anaphylaxis</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Neurological/Psychiatry: </em></p></td><td style="vertical-align:top"><p><em>&nbsp;Headache, paraesthesia</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Haematological:</em></p></td><td style="vertical-align:top"><p><em>&nbsp;Lymphopenia</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Liver/pancreas:</em></p></td><td style="vertical-align:top"><p><em>&nbsp;Elevated liver function tests, hepatic failure</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Musculoskeletal:</em></p></td><td style="vertical-align:top"><p><em>&nbsp;Myalgia, rarely myolysis, arthralgia, elevated creatine phosphokinase</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Urology: </em></p></td><td style="vertical-align:top"><p><em>&nbsp;Elevated creatinine, renal failure</em></p></td></tr></tbody></table><p>&nbsp;</p><p><em>Restarting abacavir following an abacavir HSR results in a prompt return of symptoms within hours. This recurrence of the HSR is usually more severe than on initial presentation, and may include life-threatening hypotension and death. Reactions have also occurred infrequently after restarting abacavir in patients who had only one of the key symptoms of hypersensitivity (see above) prior to stopping abacavir; and on very rare occasions have also been seen in patients who have restarted therapy with no preceding symptoms of a HSR (i.e., patients previously considered to be abacavir tolerant).</em></p><p><em>For details of clinical management in the event of a suspected abacavir HSR see Warnings and Precautions.</em></p><p><strong>To report any side effect(s):</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hotline: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p><strong>-GlaxoSmithKline - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel: +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: saudi.safety@gsk.com<u>&nbsp; </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/<u> </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O Box 55850, Jeddah 21544, Saudi Arabia.<strong> </strong></p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>-GlaxoSmithKline - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: gcc.medinfo@gsk.com</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/<u> </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabi</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Single doses up to 1200 mg and daily doses up to 1800 mg of abacavir have been administered to patients in clinical studies. No unexpected adverse reactions were reported. The effects of higher doses are not known.</p><p>If overdosage occurs the patient should be monitored for evidence of toxicity (<em>see Adverse Reactions</em>), and standard supportive treatment applied as necessary. It is not known whether abacavir can be removed by peritoneal dialysis or haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group - nucleoside analogue, ATC Code: J05A F06.</p><p>Mechanism of action</p><p>Abacavir is a nucleoside analogue reverse transcriptase inhibitor. It is a potent selective inhibitor of HIV-1 and HIV-2, including HIV-1 isolates with reduced susceptibility to zidovudine, lamivudine, zalcitabine, didanosine or nevirapine. Abacavir is metabolised intracellularly to the active moiety, carbovir 5&rsquo;-triphosphate (TP). <em>In vitro</em> studies have demonstrated that its mechanism of action in relation to HIV is inhibition of the HIV reverse transcriptase enzyme, an event which results in chain termination and interruption of the viral replication cycle. The antiviral activity of abacavir in cell culture was not antagonized when combined with the nucleoside reverse transcriptase inhibitors (NRTIs) didanosine, emtricitabine, lamivudine, stavudine, tenofovir, zalcitabine or zidovudine, the non-nucleoside reverse transcriptase inhibitor (NNRTI) nevirapine, or the protease inhibitor (PI) amprenavir.</p><p><strong><em>Pharmacodynamic effects</em></strong></p><p>In a study of 20 HIV-infected patients receiving ZIAGEN 300&nbsp;mg twice daily, with only one 300&nbsp;mg dose taken prior to the 24 hours sampling period, the geometric mean terminal carbovir-TP intracellular half-life at steady-state was 20.6 hours, compared to the geometric mean abacavir plasma half-life in this study of 2.6 hours. &nbsp;The steady state pharmacokinetic properties of <em>ZIAGEN</em> 600&nbsp;mg once daily was compared to <em>ZIAGEN</em> 300&nbsp;mg twice daily in a crossover study in 27 HIV-infected patients. Intracellular carbovir triphosphate exposures in peripheral blood mononuclear cells were higher for <em>ZIAGEN</em> 600&nbsp;mg once daily with respect to AUC24,ss(32 %, higher), Cmax 24,ss (99% higher) and trough values (18% higher), compared to the 300 mg twice daily regimen.&nbsp; These data support the use of <em>ZIAGEN</em> 600&nbsp;mg once daily for the treatment of HIV infected patients. Additionally, the efficacy and safety of <em>ZIAGEN</em> given once daily has been demonstrated in a pivotal clinical study (CNA30021- <em>see Clinical Studies</em>).</p><p>Abacavir-resistant isolates of HIV-1 have been selected <em>in vitro</em> and are associated with specific genotypic changes in the reverse transcriptase (RT) codon region (codons M184V, K65R, L74V and Y115F). Viral resistance to abacavir develops relatively slowly <em>in vitro</em> and <em>in vivo</em>, requiring multiple mutations to reach an eight-fold increase in IC<sub>50</sub> over wild-type virus, which may be a clinically relevant level.</p><p>Isolates resistant to abacavir may also show reduced sensitivity to lamivudine, zalcitabine and/or didanosine, but remain sensitive to zidovudine and stavudine. Cross resistance between abacavir and protease inhibitors or non-nucleoside reverse transcriptase inhibitors is unlikely. Treatment failure following initial therapy with abacavir, lamivudine and zidovudine is mainly associated with the M184V alone, thus maintaining many therapeutic options for a second line regimen.</p><p>Abacavir penetrates the cerebrospinal fluid (CSF) (<em>see Pharmacokinetics</em>), and has been shown to reduce HIV-1 RNA levels in the CSF. In combination with other antiretrovirals it may have a role in the prevention of HIV related neurological complications, and may delay the development of resistance in this sanctuary site.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption</p><p>Abacavir is rapidly and well absorbed following oral administration. The absolute bioavailability of oral abacavir in adults is about 83%.&nbsp; Following oral administration, the mean time (t<sub>max</sub>) to maximal serum concentrations of abacavir is about 1.5 hours for the tablet formulation and about 1 hour for the solution formulation.</p><p>There are no differences observed between the AUC for the tablet or solution. At a dosage of 300&nbsp;mg twice daily, the mean steady state C<sub>max</sub> of abacavir from tablet administration was 3.00 micrograms/ml, and the mean AUC over a dosing interval of 12&nbsp;h was 6.02 micrograms.h/ml (daily AUC of approximately 12.0 micrograms.h/ml). The C<sub>max</sub> value for the oral solution is slightly higher than the tablet.&nbsp; After a 600&nbsp;mg <em>ZIAGEN</em> tablet dose, the mean abacavir C<sub>max</sub> was approximately 4.26 micrograms/ml and the mean AUC<sub>&yen;</sub> was 11.95 micrograms.h/ml.</p><p>Food delayed absorption and decreased C<sub>max</sub> but did not affect overall plasma concentrations (AUC). Therefore <em>ZIAGEN</em> can be taken with or without food.</p><p>Administration of crushed tablets with a small amount of semi-solid food or liquid would not be expected to have an impact on the pharmaceutical quality, and would therefore not be expected to alter the clinical effect. This conclusion is based on the physiochemical and pharmacokinetic characteristics of the active ingredient and the in vitro dissolution behaviour of abacavir tablets in water, assuming that the patient crushes and transfers 100% of the tablet and ingests immediately.</p><p>Distribution</p><p>Following i.v. administration, the apparent volume of distribution was about 0.8&nbsp;l/kg, indicating that abacavir<em> </em>penetrates freely into body tissues.</p><p>Studies in HIV infected patients have shown good penetration of abacavir into the cerebrospinal fluid (CSF), with a CSF to plasma AUC ratio of between 30 to 44%. In a Phase I pharmacokinetic study, the penetration of abacavir into the CSF was investigated following administration of <em>ZIAGEN</em> 300&nbsp;mg twice a day. The mean concentration of abacavir achieved in the CSF 1.5 hours post dose was 0.14&nbsp;micrograms/ml. In a further pharmacokinetic study of 600&nbsp;mg twice a day, the CSF concentration of abacavir increased over time, from approximately 0.13&nbsp;micrograms/ml at 0.5 to 1 hour after dosing, to approximately 0.74&nbsp;micrograms/ml after 3 to 4 hours. While peak concentrations may not have been attained by 4 hours, the observed values are 9-fold greater than the IC50 of abacavir of 0.08&nbsp;micrograms/ml or 0.26 micromoles.</p><p>Plasma protein binding studies <em>in vitro</em> indicate that abacavir binds only low to moderately (circa 49%) to human plasma proteins at therapeutic concentrations. This indicates a low likelihood for drug interactions through plasma protein binding displacement.</p><p>Metabolism</p><p>Abacavir is primarily metabolised by the liver with less than 2% of the administered dose being renally excreted, as unchanged compound. The primary pathways of metabolism in man are by alcohol dehydrogenase and by glucuronidation to produce the 5&#39;-carboxylic acid and 5&#39;-glucuronide which account for about 66% of the administered dose. These metabolites are excreted in the urine.</p><p>Elimination</p><p>The mean half-life of abacavir is about 1.5 hours. Following multiple oral doses of <em>ZIAGEN</em> 300&nbsp;mg twice a day there is no significant drug accumulation. Elimination of abacavir is via hepatic metabolism with subsequent excretion of metabolites primarily in the urine. The metabolites and unchanged abacavir account for about 83% of the administered <em>ZIAGEN</em> dose in the urine the remainder is eliminated in the faeces.</p><p>Special Patient Populations</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Children</strong></p><p>Abacavir is rapidly and well absorbed from oral solution and tablet formulations administered to children. Plasma abacavir exposure has been shown to be the same for both formulations when administered at the same dose. Children receiving abacavir oral solution according to the recommended dosage regimen achieve plasma abacavir exposure similar to adults.&nbsp; Children receiving abacavir oral tablets according to the recommended dosage regimen achieve higher plasma abacavir exposure than children receiving oral solution because higher mg/kg doses are administered with the tablet formulation (see Dosage and Administration). Paediatric pharmacokinetic studies have demonstrated that once daily dosing provides equivalent AUC0-24 to twice daily dosing of the same total daily dose for both oral solution and tablet formulations.</p><p>There are insufficient safety data to recommend the use of <em>ZIAGEN</em> in infants less than 3&nbsp;months old. The limited data available indicate that a dose of 2&nbsp;mg/kg in neonates less than 30 days old provides similar or greater AUCs, compared to the 8&nbsp;mg/kg dose administered to older children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Elderly</strong></p><p>The pharmacokinetics of abacavir have not been studied in patients over 65 years of age. When treating elderly patients consideration needs to be given to the greater frequency of decreased hepatic, renal and cardiac function, and concomitant disease or other drug therapy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Renally impaired</strong></p><p>Abacavir is primarily metabolised by the liver with approximately 2% of abacavir excreted unchanged in the urine. The pharmacokinetics of abacavir in patients with end-stage renal disease is similar to patients with normal renal function. Therefore, no dosage reduction is required in patients with renal impairment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Hepatically impaired</strong></p><p>Abacavir is metabolised primarily by the liver. The pharmacokinetics of abacavir have been studied in patients with mild hepatic impairment (Child-Pugh score 5 to 6). The results showed that there was a mean increase of 1.89 fold in the abacavir AUC, and 1.58 fold in the half-life of abacavir. The AUCs of the metabolites were not modified by the liver disease. However, the rates of formation and elimination of these were decreased.</p><p>In order to achieve exposures that are within the therapeutic range of patients without liver disease, patients with mild hepatic impairment should receive 200&nbsp;mg <em>ZIAGEN</em> twice daily. The pharmacokinetics have not been studied in patients with moderate or severe hepatic impairment, therefore <em>ZIAGEN</em> is not recommended in these patient groups.</p><p>Clinical Studies</p><p>In clinical studies, treatment with abacavir in combination with zidovudine and lamivudine was associated with significant and sustained reductions in viral load, with corresponding rises in CD4 cell count in adults and children.</p><p>In a double-blind clinical study over 48 weeks in treatment na&iuml;ve adult patients, the combination of abacavir, lamivudine and zidovudine showed an equivalent antiviral effect to the combination with indinavir, lamivudine and zidovudine in the primary analysis of efficacy.&nbsp; In a secondary analysis of patients with baseline plasma HIV-1 RNA levels above 100,000 copies per ml, patients receiving the combination containing indinavir had a superior response. Patients with baseline plasma HIV-1 RNA below 100,000 copies per ml had an equivalent response to both treatments.</p><p>A once daily regimen of abacavir and lamivudine was investigated in a multicentre, double-blind, controlled study (CNA30021) of 770&nbsp;HIV-infected, therapy-na&iuml;ve adults. They were randomised to receive either <em>ZIAGEN</em> 600&nbsp;mg once daily or 300&nbsp;mg twice daily, both in combination with lamivudine 300&nbsp;mg once daily and efavirenz 600&nbsp;mg once daily. Patients were stratified at baseline based on plasma HIV-1 RNA less than or equal to100,000 copies/ml or greater than 100,000 copies/ml. The duration of double-blind treatment was at least 48&nbsp;weeks. The results are summarised in the table below.</p><p>Virological Response Based on Plasma HIV-1 RNA less than 50 copies/ml</p><p>at Week 48 ITT-Exposed Population</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Populations</p></td><td><p>ABC once/day<br />+ 3TC + EFV<br />(N = 384)</p></td><td><p>ABC twice/day<br />&nbsp;+ 3TC + EFV<br />(N = 386)</p></td></tr><tr><td style="vertical-align:top"><p>Sub-group by baseline RNA</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Less than or equal to 100,000 copies/ml</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>141/217 (65%)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>145/217 (67%)</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Greater than 100,000 copies/ml</p></td><td style="vertical-align:top"><p>112/167 (67%)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>116/169 (69%)</p></td></tr><tr><td style="vertical-align:top"><p>Total population</p></td><td style="vertical-align:top"><p>253/384 (66%)</p></td><td style="vertical-align:top"><p>261/386 (68%)</p></td></tr></tbody></table><p>The abacavir once daily group was demonstrated to be non-inferior when compared to the twice daily group in the overall and base-line viral load sub-groups. The incidence of adverse events reported were similar in the two treatment groups.</p><p>Genotypic analysis was attempted for all subjects with virologic failure (confirmed HIV RNA greater than 50 copies/ml). There was a low overall incidence of virologic failure in both the once and twice daily treatment groups (10% and 8%, respectively). Additionally, genotyping was restricted to samples with plasma HIV-1 RNA greater than 500 copies/ml. These factors resulted in a small sample size.&nbsp; Therefore, no firm conclusions could be drawn regarding differences in treatment emergent mutations between the two treatment groups.&nbsp; Reverse transcriptase amino acid residue 184 was consistently the most frequent position for NRTI resistance-associated mutations (M184V or M184I). The second most frequent mutation was L74V. Mutations Y115F and K65R were uncommon.</p><p>A randomised comparison of a regimen including once daily vs twice daily dosing of abacavir and lamivudine was undertaken within a randomised, multicentre, controlled study of HIV-infected, paediatric patients. 1206 paediatric patients aged 3 months to 17 years enrolled in the ARROW Trial (COL105677) and were dosed according to the weight - band dosing recommendations in the World Health Organisation treatment guidelines (Antiretroviral therapy of HIV infection in infants and children, 2006). After 36 weeks on a regimen including twice daily abacavir and lamivudine, 669 eligible subjects were randomised to either continue twice daily dosing or switch to once daily abacavir and lamivudine for at least 96 weeks.&nbsp; The results are summarised in the table below:</p><p>Virological Response Based on Plasma HIV-1 RNA less than 80 copies/ml at Week 48 and Week 96 in the Once Daily versus Twice Daily abacavir + lamivudine randomisation of ARROW (Observed Analysis)</p><table border="1" cellspacing="0" cellpadding="0" style="width:456px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Twice Daily</p><p>N (%)</p></td><td style="vertical-align:top"><p>Once Daily</p><p>N (%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Week 0 (After &ge;36 Weeks on Treatment)</p></td></tr><tr><td style="vertical-align:top"><p>Plasma HIV-1 RNA &lt;80 c/mL</p></td><td style="vertical-align:top"><p>250/331 (76)</p></td><td style="vertical-align:top"><p>237/335 (71)</p></td></tr><tr><td style="vertical-align:top"><p>Risk difference (once daily-twice daily)</p></td><td colspan="2" style="vertical-align:top"><p>-4.8% (95% CI -11.5% to +1.9%), p=0.16</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Week 48</p></td></tr><tr><td style="vertical-align:top"><p>Plasma HIV-1 RNA &lt;80 c/mL</p></td><td style="vertical-align:top"><p>242/331 (73)</p></td><td style="vertical-align:top"><p>236/330 (72)</p></td></tr><tr><td style="vertical-align:top"><p>Risk difference (once daily-twice daily)</p></td><td colspan="2" style="vertical-align:top"><p>-1.6% (95% CI -8.4% to +5.2%), p=0.65</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Week 96</p></td></tr><tr><td style="vertical-align:top"><p>Plasma HIV-1 RNA &lt;80 c/mL</p></td><td style="vertical-align:top"><p>234/326 (72)</p></td><td style="vertical-align:top"><p>230/331 (69)</p></td></tr><tr><td style="vertical-align:top"><p>Risk difference (once daily-twice daily)</p></td><td colspan="2" style="vertical-align:top"><p>-2.3% (95% CI -9.3% to +4.7%), p=0.52</p></td></tr></tbody></table><p>&nbsp;</p><p>The abacavir/lamivudine once daily dosing group was demonstrated to be non-inferior to the twice daily group according to the pre-specified non-inferiority margin of -12%, for the primary endpoint of &lt;80 c/mL at Week 48 as well as at Week 96 (secondary endpoint) and all other thresholds tested (&lt;200c/mL, &lt;400c/mL, &lt;1000c/mL), which all fell well within this non-inferiority margin. Subgroup analyses testing for heterogeneity of once vs twice daily demonstrated no significant effect of sex, age, or viral load at randomisation. Conclusions supported non-inferiority regardless of analysis method.</p><p>In a study comparing unblinded NRTI combinations (with or without blinded nelfinavir) in children, a significantly greater proportion treated with abacavir and lamivudine (73%) or abacavir and zidovudine (70%) had HIV-1 RNA less than or equal to 400 copies/ml at 24 weeks, compared with those treated with lamivudine and zidovudine (44%).&nbsp; In children with extensive antiretroviral exposure, a modest but sustained effect of the combination of abacavir, lamivudine and zidovudine was observed.</p><p>In therapy experienced patients, limited data show that the addition of abacavir to nucleoside reverse transcriptase inhibitors provides additional benefit in reducing viral load, and increasing CD4 cell count. The degree of benefit will depend on the nature and duration of prior therapy which may have selected for cross resistance to abacavir.</p><p>Antiretroviral Pregnancy Registry</p><p>The Antiretroviral Pregnancy Registry has received prospective reports of over 2,000 exposures to abacavir during pregnancy resulting in live birth. These consist of over 800 exposures during the first trimester, over 1,100 exposures during the second/third trimester and included 27 and 32 birth defects respectively. The prevalence (95% CI) of defects in the first trimester was 3.1% (2.0, 4.4%) and in the second/third trimester, 2.7% (1.9, 3.9%). Among pregnant women in the reference population, the background rate of birth defects is 2.7%. There was no association between abacavir and overall birth defects observed in the Antiretroviral Pregnancy Registry</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carcinogenesis, mutagenesis</p><p>Abacavir was not mutagenic in bacterial tests but showed activity <em>in vitro</em> in the human lymphocyte chromosome aberration assay, the mouse lymphoma assay, and the <em>in vivo</em> micronucleus test. This is consistent with the known activity of other nucleoside analogues. These results indicate that abacavir is a weak clastogen both <em>in vitro</em> and <em>in vivo</em> at high test concentrations.</p><p>Carcinogenicity studies with orally administered abacavir in mice and rats showed an increase in the incidence of malignant and non-malignant tumours. Malignant tumours occurred in the preputial gland of males and the clitoral gland of females of both species, and in the liver, urinary bladder, lymph nodes and the subcutis of female rats.</p><p>The majority of these tumours occurred at the highest abacavir dose of 330&nbsp;mg/kg/day in mice and 600&nbsp;mg/kg/day in rats. These dose levels were equivalent to 24 to 32 times the expected systemic exposure in humans. The exception was the preputial gland tumour which occurred at a dose of 110&nbsp;mg/kg. This is equivalent to six times the expected human systemic exposure. There is no structural counterpart for this gland in humans. While the carcinogenic potential in humans is unknown, these data suggest that a carcinogenic risk to humans is outweighed by the potential clinical benefit.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reproductive toxicology</p><p>Placental transfer of abacavir and/or its related metabolites has been shown to occur in animals. Evidence of toxicity to the developing embryo and foetuses occurred only in rats at maternally toxic doses of 500&nbsp;mg/kg/day and above. This dose is equivalent to 32 to 35 times human therapeutic exposure based on AUC. The findings included foetal oedema, variations and malformations, resorptions, decreased foetal body weight and an increase in still births. The dose at which there were no effects on pre or post-natal development was 160&nbsp;mg/kg/day. This dose is equivalent to an exposure of about 10 times that in humans. Similar findings were not observed in rabbits.</p><p>A fertility study in the rat has shown that doses up to 500&nbsp;mg/kg of abacavir had no effect on male or female fertility.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Animal toxicology and/or pharmacology </strong></p><p>Mild myocardial degeneration in the heart of mice and rats was observed following administration of abacavir for two years. The systemic exposures were equivalent to 7 to 24 times the expected systemic exposure in humans. The clinical relevance of this finding has not been determined</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Oral Solution</strong></p><p>Sorbitol (34%)</p><p>Saccharin sodium</p><p>Sodium citrate</p><p>Citric acid anhydrous</p><p>Methyl parahydroxybenzoate (E218)</p><p>Propyl parahydroxybenzoate (E216)</p><p>Propylene glycol</p><p>Artificial strawberry and banana flavour</p><p>Purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date is indicated on the packaging.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The storage conditions are detailed on the packaging</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>ZIAGEN</em> oral solution is supplied in high density polyethylene bottles with child-resistant closures, containing 240&nbsp;ml of oral solution. A 10&nbsp;ml oral dosing syringe and an adapter are also included in the pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>An oral dosing syringe is provided for accurate measurement of the prescribed dose of <em>ZIAGEN</em> oral solution. Instructions for use are included in the pack.</p><p>Discard <em>ZIAGEN</em> oral solution two months after first opening.</p><p>Not all presentations are available in every country.</p><p>&nbsp;</p><p style="text-align:center"><strong>MANDATORY GLOBAL PACKAGING COMPONENTS</strong></p><p style="text-align:center"><strong>Alert Card</strong></p><table border="1" align="center" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p style="text-align:center"><strong>IMPORTANT ALERT CARD</strong></p><p style="text-align:center"><strong><em>ZIAGEN</em></strong><strong><sup>TM</sup></strong><strong> (abacavir sulfate) tablets or oral solution</strong></p><p style="text-align:center"><strong>Carry this card with you at all times</strong></p></td></tr></tbody></table><p style="text-align:center"><span style="text-align:unset">Patients taking </span><em style="text-align:unset">ZIAGEN</em><span style="text-align:unset"> may develop a hypersensitivity reaction (serious allergic reaction)</span><strong style="text-align:unset"> </strong><span style="text-align:unset">which </span><strong style="text-align:unset">can be life threatening </strong><span style="text-align:unset">if treatment with </span><em style="text-align:unset">ZIAGEN</em><span style="text-align:unset"> is continued. </span><strong style="text-align:unset">CONTACT YOUR DOCTOR IMMEDIATELY for advice on whether you should stop taking <em>ZIAGEN</em> if</strong><span style="text-align:unset">:</span></p><p><strong>1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you get a skin rash OR</strong></p><p><strong>2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you get one or more symptoms from at least TWO of the following groups</strong></p><p><strong>-&nbsp; </strong>fever</p><p><strong>-&nbsp; </strong>shortness of breath, sore throat or cough</p><p><strong>-&nbsp; </strong>nausea or vomiting or diarrhoea or abdominal pain</p><p><strong>-&nbsp; </strong>severe tiredness or achiness or generally ill feeling</p><p>If you have discontinued <em>ZIAGEN </em>due to this reaction, <strong>YOU MUST NEVER</strong> take <em>ZIAGEN</em> or any other medicine containing abacavir (<em>KIVEXA</em>, <em>TRIZIVIR , or TRIUMEQ</em>) again, as <strong>within hours</strong> you may experience a life-threatening lowering of your blood pressure or death.</p><p><strong>CARTON PANEL</strong></p><p>The following text must be included on one of the carton panels:</p><p><strong>Detach enclosed Alert Card, it contains important safety information.</strong></p><p>WARNING! In case of any symptoms suggesting hypersensitivity reactions, contact your doctor IMMEDIATELY.</p><p>&ldquo;<strong>Pull here</strong>&rdquo; (with Alert card attached).</p><p>&nbsp;</p><p>&nbsp;ZIAGEN is trademark owned by or licensed to the ViiV Healthcare group of companies.</p><p>&copy; 2021 GSK group of companies. All right reserved.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by: 
Bora Pharmaceutical Services Inc. Mississauga, Canada
Packed by: 
Bora Pharmaceutical Services Inc. Mississauga, Canada
Marketing Authorisation Holder  
Glaxo Saudi Arabia Ltd.* Jeddah, KSA.
Address: P.O. Box 22617 Jeddah 21416 – Kingdom of Saudi Arabia.
*member of the GlaxoSmithKline group of companies 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Version number: GDS 32 / IPI 13
Date of issue:  11 May 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>